Previous 10 | Next 10 |
SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, toda...
SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, a...
SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, a...
SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL) , a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the ...
The following slide deck was published by Artelo Biosciences, Inc. in conjunction with this event. For further details see: Artelo Biosciences (ARTL) Investor presentations - Slideshow
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16 th - 20 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Spring in...
SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endoc...
SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D...
Artelo Biosciences press release (NASDAQ:ARTL): Q1 GAAP EPS of -$0.05 beats by $0.03. Company had approximately $23.5 million in cash and investments, compared to $25.6 million as of December 31, 2021. For further details see: Artelo Biosciences GAAP EPS of -$0.05 beats by $0.03
$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 Results of Phase 1b CAReS Trial Anticipated in Q3 2022 SOLANA BEACH, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Artelo ...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...